Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
TRPC6 inhibitor
- Development stage
- Preclinical
- Lead developer
- Boehringer Ingelheim
- Modality
- Small Molecules
- Administration
- Oral, Intravenous, Intraperitoneal, Subcutaneous
01
Overview
Cardurion Pharmaceuticals is developing a small molecule inhibitor of the Transient Receptor Potential Canonical-6 (TRPC6) ion channel for the treatment of cardiopulmonary indications. TRPC6 is a non-selective cation channel that facilitates the influx of calcium and sodium into cells, playing a critical role in the pathological remodeling of cardiac and pulmonary tissues. Overactivation of TRPC6 has been implicated in the progression of heart failure and pulmonary hypertension. By inhibiting this channel, Cardurion aims to mitigate maladaptive signaling pathways and provide a novel therapeutic approach for cardiovascular diseases with significant unmet needs. The program is currently in the preclinical discovery phase as part of the company's internal pipeline expansion.
- Other names
- TRPC6 InhibitorTRPC-6 InhibitorTRPC 6 Inhibitor
02
Targets
TRPC6 (Transient receptor potential canonical type 6)
Beyond the preview
Go deeper on TRPC6 inhibitor.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on TRPC6 inhibitor.